-DOCSTART- -X- O
Background. -X- _ O
Human -X- _ B-Intervention
metapneumovirus -X- _ I-Intervention
( -X- _ I-Intervention
HMPV -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
newly -X- _ O
identified -X- _ O
pulmonary -X- _ O
pathogen -X- _ O
that -X- _ O
can -X- _ O
cause -X- _ O
fatal -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
disease -X- _ O
( -X- _ O
LRD -X- _ O
) -X- _ O
in -X- _ O
hematopoietic -X- _ B-Patient
cell -X- _ I-Patient
transplantation -X- _ I-Patient
( -X- _ I-Patient
HCT -X- _ I-Patient
) -X- _ I-Patient
recipients. -X- _ I-Patient
Little -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
progression -X- _ O
rates -X- _ O
from -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
( -X- _ O
URI -X- _ O
) -X- _ O
to -X- _ O
LRD -X- _ O
and -X- _ O
risk -X- _ O
factors -X- _ O
associated -X- _ O
with -X- _ O
progression. -X- _ O
Methods. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
118 -X- _ B-Patient
HCT -X- _ I-Patient
recipients -X- _ I-Patient
receiving -X- _ O
transplantation -X- _ O
between -X- _ O
2004 -X- _ O
and -X- _ O
2014 -X- _ O
who -X- _ O
had -X- _ O
HMPV -X- _ O
detected -X- _ O
in -X- _ O
nasopharyngeal -X- _ O
, -X- _ O
bronchoalveolar -X- _ O
lavage -X- _ O
, -X- _ O
or -X- _ O
lung -X- _ O
biopsy -X- _ O
samples -X- _ O
by -X- _ O
real-time -X- _ O
reverse -X- _ O
transcription -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
were -X- _ O
retrospectively -X- _ O
analyzed. -X- _ O
Results. -X- _ O
More -X- _ B-Outcome
than -X- _ I-Outcome
90 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
cases -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
between -X- _ I-Outcome
December -X- _ I-Outcome
and -X- _ I-Outcome
May. -X- _ I-Outcome
Among -X- _ I-Outcome
the -X- _ I-Outcome
118 -X- _ I-Outcome
HCT -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
88 -X- _ I-Outcome
and -X- _ I-Outcome
30 -X- _ I-Outcome
had -X- _ I-Outcome
URI -X- _ I-Outcome
alone -X- _ I-Outcome
and -X- _ I-Outcome
LRD -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Among -X- _ I-Outcome
30 -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
LRD -X- _ I-Outcome
, -X- _ I-Outcome
17 -X- _ I-Outcome
patients -X- _ I-Outcome
progressed -X- _ I-Outcome
from -X- _ I-Outcome
URI -X- _ I-Outcome
to -X- _ I-Outcome
LRD -X- _ I-Outcome
after -X- _ I-Outcome
a -X- _ I-Outcome
median -X- _ I-Outcome
of -X- _ I-Outcome
7 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
2–63 -X- _ I-Outcome
days -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
probability -X- _ I-Outcome
of -X- _ I-Outcome
progression -X- _ I-Outcome
to -X- _ I-Outcome
LRD -X- _ I-Outcome
within -X- _ I-Outcome
40 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
URI -X- _ I-Outcome
was -X- _ I-Outcome
16 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
Cox -X- _ I-Outcome
regression -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
steroid -X- _ I-Outcome
use -X- _ I-Outcome
≥1 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
kg -X- _ I-Outcome
prior -X- _ I-Outcome
to -X- _ I-Outcome
URI -X- _ I-Outcome
diagnosis -X- _ I-Outcome
( -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
[ -X- _ I-Outcome
HR -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
5.10 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.004 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
low -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
count -X- _ I-Outcome
( -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
3.43 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.011 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
early -X- _ I-Outcome
onset -X- _ I-Outcome
of -X- _ I-Outcome
HMPV -X- _ I-Outcome
infection -X- _ I-Outcome
after -X- _ I-Outcome
HCT -X- _ I-Outcome
( -X- _ I-Outcome
before -X- _ I-Outcome
day -X- _ I-Outcome
30 -X- _ I-Outcome
after -X- _ I-Outcome
HCT -X- _ I-Outcome
; -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
3.54 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.013 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
progression -X- _ I-Outcome
to -X- _ I-Outcome
LRD. -X- _ I-Outcome
The -X- _ I-Outcome
median -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
nasal -X- _ I-Outcome
wash -X- _ I-Outcome
samples -X- _ I-Outcome
was -X- _ I-Outcome
1.1 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
6 -X- _ I-Outcome
) -X- _ I-Outcome
copies -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
( -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
3.3 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
) -X- _ I-Outcome
–1.7 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
9 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
correlation -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
and -X- _ I-Outcome
progression. -X- _ I-Outcome
Conclusions. -X- _ I-Outcome
Progression -X- _ I-Outcome
from -X- _ I-Outcome
URI -X- _ I-Outcome
to -X- _ I-Outcome
LRD -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
up -X- _ I-Outcome
to -X- _ I-Outcome
60 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
HCT -X- _ I-Outcome
recipients -X- _ I-Outcome
with -X- _ I-Outcome
risk -X- _ I-Outcome
factors -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
systemic -X- _ I-Outcome
corticosteroid -X- _ I-Outcome
use -X- _ I-Outcome
or -X- _ I-Outcome
low -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
counts. -X- _ I-Outcome
Further -X- _ O
studies -X- _ O
are -X- _ O
needed -X- _ O
to -X- _ O
define -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
viral -X- _ O
load -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
progressive -X- _ O
disease -X- _ O
. -X- _ O

